Agile Therapeutics, Inc. (AGRX) Price Target Increased to $10.00 by Analysts at Royal Bank Of Canada
Agile Therapeutics, Inc. (NASDAQ:AGRX) had its price target boosted by equities researchers at Royal Bank Of Canada from $8.00 to $10.00 in a research report issued to clients and investors on Thursday. The firm currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 185.71% from the stock’s current price.
A number of other brokerages have also recently issued reports on AGRX. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Sunday, July 30th. Janney Montgomery Scott reissued a “buy” rating and set a $13.00 price objective on shares of Agile Therapeutics in a report on Thursday, September 7th. HC Wainwright started coverage on Agile Therapeutics in a report on Wednesday, July 19th. They set a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine cut Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Agile Therapeutics has a consensus rating of “Buy” and an average price target of $9.08.
Agile Therapeutics (AGRX) opened at 3.50 on Thursday. The stock’s 50 day moving average is $3.65 and its 200 day moving average is $3.43. The company’s market cap is $100.82 million. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $7.95.
Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same period in the prior year, the firm earned ($0.29) earnings per share. On average, analysts predict that Agile Therapeutics will post ($1.03) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/14/agile-therapeutics-inc-agrx-price-target-increased-to-10-00-by-analysts-at-royal-bank-of-canada.html.
In related news, Chairman Alfred Altomari acquired 10,000 shares of the business’s stock in a transaction on Friday, August 25th. The stock was bought at an average cost of $3.34 per share, with a total value of $33,400.00. Following the completion of the acquisition, the chairman now owns 161,587 shares in the company, valued at $539,700.58. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.50% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada lifted its holdings in shares of Agile Therapeutics by 608.0% during the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after acquiring an additional 27,907 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of Agile Therapeutics during the second quarter valued at $122,000. Susquehanna International Group LLP bought a new position in shares of Agile Therapeutics during the second quarter valued at $205,000. LMR Partners LLP bought a new position in shares of Agile Therapeutics during the second quarter valued at $211,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Agile Therapeutics during the second quarter valued at $309,000. 67.59% of the stock is owned by institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.